4 Biotech Stocks Finish Big

In this video, health care analysts David Williamson and Max Macaluso discuss some of the biggest movers at the end of last week. We have upgrades, downgrades, and clinical trial action impacting several popular stocks. Watch and find out why these stocks moved and what it means for investors.

Many investors to volatile small-cap biotechs since they hold the allure of substantial short term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Editor's note: Novartis' Sandostatin fourth-quarter sales of $374 million are misstated as its full year sales, instead of $1.4 billion. The Fool regrets the error. 

Dave Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 16, 2012, at 6:36 PM, Mikey925 wrote:

    Sorry guys, but EXAS is not developing a drug. They are developing a non-invasive SCREENING TEST for colorectal cancer, the #2 killer of Americans over the age of 50 that costs Medi-Care $14 Billion annually to treat.

    Wedbush downgraded them from Outperform to a Neutral on a "valuation" basis given the stock's 50% run this year. No other analyst has followed suit.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2060507, ~/Articles/ArticleHandler.aspx, 10/26/2016 11:27:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,226.59 57.32 0.32%
S&P 500 2,144.51 1.35 0.06%
NASD 5,277.07 -6.33 -0.12%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 11:06 AM
AEGR $2.03 Up +0.02 +1.00%
Aegerion Pharmaceu… CAPS Rating: **
EXAS $17.03 Down -2.57 -13.09%
EXACT Sciences CAPS Rating: **
LXRX $15.84 Down -0.02 -0.13%
Lexicon Pharmaceut… CAPS Rating: **
NVS $71.59 Down -1.04 -1.43%
Novartis CAPS Rating: ****
XNPT.DL $0.00 Down +0.00 +0.00%
XenoPort CAPS Rating: ***